By accepting you will be accessing a service provided by a third-party external to https://mschristian.org/

In MS Patients, Ozanimod Surpasses Avonex at Reducing Relapses, Phase 3 Trial Finds - Multiple Sclerosis News Today

In MS Patients, Ozanimod Surpasses Avonex at Reducing Relapses, Phase 3 Trial Finds  Multiple Sclerosis News Today

Oral ozanimod is more effective at reducing the frequency of relapses than Avonex (interferon beta-1a) in patients with relapsing forms of Multiple Sclerosis (MS), ...

Compound Created to Help Reconstruct Myelin in Mul...
Ofatumumab Bests Teriflunomide in Head-to-Head MS ...
 

Comments

No comments made yet. Be the first to submit a comment
Already Registered? Login Here
Guest
Monday, 25 May 2020

Captcha Image


MSChristian.org RSS Statement

Most of the information found on this website comes from RSS Feeds. It is an automated task that provides the information to you. We try to limit items that are duplicates, but with many feeds this can be difficult. Since the owner of this website also has MS and is legally blind this service was necessary to keep the website running with as much automation as possible. Volunteers help from time to time but many have disabilities themselves. We thank you for visiting us and hope that MSC can be of service to you and your loved ones.